Vanguard Group Inc Reneo Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 882,104 shares of RPHM stock, worth $1.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

882,104

Previous 882,104 -0.0%

Holding current value

$1.48 Million

Previous $1.33 Million 12.62%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.51 - $1.9 $133,924 - $168,514	-88,692 Reduced 9.14%	882,104 $1.33 Million
Q1 2024 May 10, 2024	SELL	$1.59 - $1.74 $12,867 - $14,081	-8,093 Reduced 0.83%	970,796 $1.61 Million
Q4 2023 Feb 14, 2024	BUY	$1.34 - $8.43 $5,014 - $31,545	3,742 Added 0.38%	978,889 $1.57 Million
Q3 2023 Nov 14, 2023	BUY	$5.44 - $8.13 $94,079 - $140,600	17,294 Added 1.81%	975,147 $7.43 Million
Q2 2023 Aug 14, 2023	BUY	$5.44 - $10.5 $3.48 Million - $6.72 Million	639,871 Added 201.23%	957,853 $6.28 Million
Q4 2022 Feb 10, 2023	SELL	$1.8 - $3.52 $1,497 - $2,928	-832 Reduced 0.26%	317,982 $740,000
Q2 2022 Aug 12, 2022	SELL	$1.96 - $3.04 $82,451 - $127,883	-42,067 Reduced 11.66%	318,814 $845,000
Q1 2022 May 13, 2022	SELL	$2.94 - $9.07 $19,742 - $60,905	-6,715 Reduced 1.83%	360,881 $1.06 Million
Q4 2021 Feb 14, 2022	SELL	$6.07 - $9.68 $61,652 - $98,319	-10,157 Reduced 2.69%	367,596 $3.14 Million
Q3 2021 Nov 12, 2021	BUY	$6.28 - $11.07 $72,490 - $127,781	11,543 Added 3.15%	377,753 $2.82 Million
Q2 2021 Aug 13, 2021	BUY	$7.78 - $15.0 $2.85 Million - $5.49 Million	366,210 New	366,210 $3.42 Million

Others Institutions Holding RPHM

# of Institutions

Shares Held

31M

Call Options Held

50.8K

Put Options Held

View Full List

About Reneo Pharmaceuticals, Inc.

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

More about RPHM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Reneo Pharmaceuticals, Inc. Transaction History